Analyst consensus rating
Cytokinetics Analyst Rating: Strong Buy
CYTK is rated Strong Buy by 20 analysts with a $109.90 target. As of 2026-08-27.
Direct answer
Cytokinetics's consensus rating is Strong Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $109.90.
Forecast evidence checked August 27, 2026.
Get free Cytokinetics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $79.20
- Average price target
- $109.90
- High price target
- $146.00
- Low price target
- $85.00
- Low target gap
- +7.3%
- Target upside
- +38.8%
- High target gap
- +84.3%
- Target range width
- 77%
- Consensus rating
- Strong Buy
- Analysts
- 20
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cytokinetics?
Cytokinetics has a verified Strong Buy consensus. The same dataset has an average price target of $109.90.
How far are Cytokinetics's low and high targets from the recorded price?
The low target implies +7.3%, while the high target implies +84.3%.
How many analysts are included in Cytokinetics's consensus?
The verified consensus includes 20 analysts.
How is Cytokinetics's target upside or downside calculated?
The average target of $109.90 is divided by the recorded price of $79.20, then one is subtracted to produce +38.8%. This does not guarantee a future return.
When was Cytokinetics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.